Educational content only. This post explains, in general terms, how private-equity-backed acquirers evaluate healthcare practices. It describes broad market patterns drawn from published M&A commentary, not the terms of any specific deal, and it is not legal, tax, financial, or transaction advice. Deal structures and valuations vary by transaction, specialty, province, and state, and change over time. Consult your accountant, lender, and qualified transaction advisors before making any significant business or financial decision.
Private equity involvement in healthcare practice consolidation has accelerated across multiple specialties in both Canada and the US over the past decade. Dental, physical therapy, optometry, audiology, and dermatology have all seen significant PE-backed consolidation activity. An independent operator encounters this in one of two ways: as a potential seller of their practice, or as a competitor whose resources change the local landscape.
Understanding how PE-backed acquirers evaluate a practice, meaning what they are buying, how they price it, and how the transaction is structured, is useful for any independent operator, whether or not a sale is ever contemplated. This post covers how these buyers think. For the broader picture of how consolidation works across specialties, including the regulatory structures and the US and Canadian differences, see our overview of how healthcare consolidation works.
What These Buyers Are Acquiring
PE-backed healthcare consolidation is generally driven by two related investment ideas: the platform-and-add-on model, and multiple arbitrage.
In the platform-and-add-on model, an acquirer builds a large multi-site platform from an initial platform practice, then adds smaller practices to it over time. The platform's value comes from scale, operational infrastructure, geographic coverage, and the ability to command a higher multiple from a larger institutional or strategic buyer at exit. The smaller add-on practices are generally acquired at lower multiples than the assembled platform eventually commands.
Multiple arbitrage describes the result of that spread. A large, well-systematized multi-site group tends to sell at a higher multiple than a small individual practice with the same EBITDA margin. Acquiring practices individually at lower multiples and selling the combined platform at a higher one is a primary return driver in healthcare consolidation. The exact multiples vary by specialty, by deal size, and by market conditions, and an operator weighing this should rely on current transaction data for their own specialty rather than a general figure.
How These Buyers Evaluate an Individual Practice
A PE-backed acquirer generally applies more rigorous and standardized evaluation criteria than an individual practitioner buyer, because it is assessing each acquisition against a platform thesis rather than personal fit. Three criteria tend to matter most.
EBITDA quality and consistency. These buyers normalize EBITDA carefully, removing non-recurring items, adjusting owner compensation to market rates, and examining the cost structure for anomalies. Underwriting often applies a discount to historical EBITDA to reflect the buyer's assessment of post-acquisition revenue risk. The result is that the earnings figure a buyer underwrites can differ meaningfully from the earnings an owner sees on their own statements.
Scalability and systematization. A practice that runs through documented systems is worth more to this kind of buyer than one that runs through the owner personally. Documented protocols, trained staff, and transferable patient relationships fit the platform model. A practice where everything depends on the owner does not, and it is discounted accordingly.
Geography and density. Consolidators tend to prioritize markets where they can build density. Several locations in the same metropolitan market create efficiencies in marketing, staffing, and administration that scattered single acquisitions do not.
How These Transactions Are Structured
PE-backed practice acquisitions frequently include an earnout, meaning a portion of the purchase price contingent on post-sale revenue or earnings performance. Earnouts are more common in these transactions than in individual practitioner purchases, reflecting the buyer's interest in managing transition risk.
Equity rollover is also common, where the selling practitioner retains a minority stake in the acquiring platform rather than taking all proceeds in cash. The stated rationale is that the seller stays involved in the platform's growth and participates in its eventual sale. The value of rollover equity depends entirely on the platform's eventual exit, which is uncertain, and it is typically illiquid and subject to the terms set by the platform and its investors in the interim.
Because a consolidator offer can combine guaranteed cash, an at-risk earnout, rollover equity, and sometimes compensation for continuing to practice, the components are worth separating before comparing it to any other offer. Our overview covers how to read an offer on consistent terms in more detail.
What This Means for an Independent Operator
Consolidation activity in a specialty has one clear benefit for the independents who remain: it establishes market comparables that would not otherwise exist. Transaction data describing what these buyers have paid for practices in a given specialty gives an independent operator a reference point for any valuation discussion, regardless of who an eventual buyer turns out to be.
The competitive side is the other half of the picture. PE-backed multi-site groups generally have access to capital, technology, and marketing infrastructure that an independent practice does not, and in a consolidated specialty that affects patient acquisition, staffing, and the benefit packages available to attract employees. Whether and how to respond is a strategic question specific to each operator's market, not a one-size answer.
See where your practice's implied value sits relative to published transaction data, including data from consolidator-driven transactions that affect market multiples in your specialty. The reference shows how a multiple is applied to normalized EBITDA, separate Canadian and US models, no account required.
Disclaimer: This content is general and educational and varies by deal, specialty, province, and state. It describes broad market patterns and changes over time. This content is not legal, tax, financial, or transaction advice, recommends no specific decision or party, and does not constitute brokerage or advisory services. Consult qualified legal, tax, and transaction professionals before evaluating any offer.